Faculty of Chemical Engineering, Biotechnology Department, Tarbiat Modares University, Tehran, Iran.
Department of Bioengineering, University of California, La Jolla, California, USA.
Biotechnol J. 2021 Aug;16(8):e2100019. doi: 10.1002/biot.202100019. Epub 2021 Jul 3.
Monoclonal antibodies (mABs) have emerged as one of the most important therapeutic recombinant proteins in the pharmaceutical industry. Their immunogenicity and therapeutic efficacy are influenced by post-translational modifications, specifically the glycosylation process. Bioprocess conditions can influence the intracellular process of glycosylation. Among all the process conditions that have been recognized to affect the mAB glycoforms, the detailed mechanism underlying how ammonium could perturb glycosylation remains to be fully understood. It was shown that ammonium induces heterogeneity in protein glycosylation by altering the sialic acid content of glycoproteins. Hence, understanding this mechanism would aid pharmaceutical manufacturers to ensure consistent protein glycosylation.
Three different mechanisms have been proposed to explain how ammonium influences the sialylation process. In the first, the inhibition of CMP-sialic acid transporter, which transports CMP-sialic acid (sialylation substrate) into the Golgi, by an increase in UDP-GlcNAc content that is brought about by the augmented incorporation of ammonium into glucosamine formation. In the second, ammonia diffuses into the Golgi and raises its pH, thereby decreasing the sialyltransferase enzyme activity. In the third, the reduction of sialyltransferase enzyme expression level in the presence of ammonium. We employed these mechanisms in a novel integrated modular platform to link dynamic alteration in mAB sialylation process with extracellular ammonium concentration to elucidate how ammonium alters the sialic acid content of glycoproteins.
Our results show that the sialylation reaction rate is insensitive to the first mechanism. At low ammonium concentration, the second mechanism is the controlling mechanism in mAB sialylation and by increasing the ammonium level (< 8 mM) the third mechanism becomes the controlling mechanism. At higher ammonium concentrations (> 8 mM) the second mechanism becomes predominant again.
The presented model in this study provides a connection between extracellular ammonium and the monoclonal antibody sialylation process. This computational tool could help scientists to develop and formulate cell culture media. The model illustrated here can assist the researchers to select culture media that ensure consistent mAB sialylation.
单克隆抗体 (mAB) 已成为制药行业最重要的治疗性重组蛋白之一。它们的免疫原性和治疗效果受到翻译后修饰的影响,特别是糖基化过程。生物工艺条件会影响糖基化的细胞内过程。在所有已被认为会影响 mAB 糖型的工艺条件中,关于氨如何干扰糖基化的详细机制仍未完全了解。研究表明,氨通过改变糖蛋白中唾液酸的含量,使蛋白质糖基化产生异质性。因此,了解这一机制将有助于制药商确保蛋白质糖基化的一致性。
有三种不同的机制被提出来说明氨如何影响唾液酸化过程。第一种机制是,随着氨被掺入到葡萄糖胺的形成中,UDP-GlcNAc 含量增加,从而抑制将 CMP-唾液酸(唾液酸化底物)转运到高尔基体的 CMP-唾液酸转运蛋白。第二种机制是,氨扩散到高尔基体并提高其 pH 值,从而降低唾液酸转移酶的酶活性。第三种机制是,在存在氨的情况下,降低唾液酸转移酶的表达水平。我们在一个新的集成模块化平台中采用了这些机制,将 mAB 唾液酸化过程中动态变化的外铵浓度与细胞外氨浓度联系起来,以阐明氨如何改变糖蛋白中的唾液酸含量。
我们的结果表明,唾液酸化反应速率对第一种机制不敏感。在低氨浓度下,第二种机制是 mAB 唾液酸化的控制机制,随着氨水平的增加(<8 mM),第三种机制成为控制机制。在较高的氨浓度(>8 mM)下,第二种机制再次占主导地位。
本研究提出的模型提供了细胞外氨与单克隆抗体唾液酸化过程之间的联系。这种计算工具可以帮助科学家开发和配制细胞培养基。这里展示的模型可以帮助研究人员选择确保 mAB 唾液酸化一致的培养基。